Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 3
2013 2
2014 2
2015 2
2016 5
2017 6
2018 4
2019 1
2020 4
2021 4
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

40 results
Results by year
Filters applied: . Clear all
Page 1
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werlé N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacquement H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C, Blay JY. Italiano A, et al. Among authors: bessede a. Lancet Oncol. 2020 Mar;21(3):446-455. doi: 10.1016/S1470-2045(19)30825-3. Epub 2020 Feb 17. Lancet Oncol. 2020. PMID: 32078813 Free PMC article. Clinical Trial.
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.
Loriot Y, Marabelle A, Guégan JP, Danlos FX, Besse B, Chaput N, Massard C, Planchard D, Robert C, Even C, Khettab M, Tselikas L, Friboulet L, André F, Nafia I, Le Loarer F, Soria JC, Bessede A, Italiano A. Loriot Y, et al. Among authors: bessede a. Ann Oncol. 2021 Nov;32(11):1381-1390. doi: 10.1016/j.annonc.2021.08.1748. Epub 2021 Aug 18. Ann Oncol. 2021. PMID: 34416362
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.
Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Sautès-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria JC, Bellera C, Sofeu C, Bessede A, Fridman WH, Loarer FL, Italiano A. Vanhersecke L, et al. Among authors: bessede a. Nat Cancer. 2021 Aug;2(8):794-802. doi: 10.1038/s43018-021-00232-6. Epub 2021 Aug 12. Nat Cancer. 2021. PMID: 35118423 Free PMC article.
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Toulmonde M, Penel N, Adam J, Chevreau C, Blay JY, Le Cesne A, Bompas E, Piperno-Neumann S, Cousin S, Grellety T, Ryckewaert T, Bessede A, Ghiringhelli F, Pulido M, Italiano A. Toulmonde M, et al. Among authors: bessede a. JAMA Oncol. 2018 Jan 1;4(1):93-97. doi: 10.1001/jamaoncol.2017.1617. JAMA Oncol. 2018. PMID: 28662235 Free PMC article. Clinical Trial.
Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.
Bessede A, Marabelle A, Guégan JP, Danlos FX, Cousin S, Peyraud F, Chaput N, Spalato M, Roubaud G, Cabart M, Khettab M, Chaibi A, Rey C, Nafia I, Mahon FX, Soria JC, Italiano A. Bessede A, et al. Ann Oncol. 2022 May 30:S0923-7534(22)01208-X. doi: 10.1016/j.annonc.2022.05.010. Online ahead of print. Ann Oncol. 2022. PMID: 35654248
GEMSP: a new therapeutic approach to multiple sclerosis.
Geffard M, Duleu S, Bessede A, Vigier V, Bodet D, Mangas A, Covenas R. Geffard M, et al. Among authors: bessede a. Cent Nerv Syst Agents Med Chem. 2012 Sep;12(3):173-81. doi: 10.2174/187152412802430110. Cent Nerv Syst Agents Med Chem. 2012. PMID: 22533511 Review.
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, Penel N, Bertucci F, Toulmonde M, Bellera C, Guegan JP, Rey C, Sautès-Fridman C, Bougoüin A, Cantarel C, Kind M, Spalato M, Dadone-Montaudie B, Le Loarer F, Blay JY, Fridman WH. Italiano A, et al. Among authors: bessede a. Nat Med. 2022 Jun;28(6):1199-1206. doi: 10.1038/s41591-022-01821-3. Epub 2022 May 26. Nat Med. 2022. PMID: 35618839 Clinical Trial.
The kynurenine pathway in brain tumor pathogenesis.
Adams S, Braidy N, Bessede A, Brew BJ, Grant R, Teo C, Guillemin GJ. Adams S, et al. Among authors: bessede a. Cancer Res. 2012 Nov 15;72(22):5649-57. doi: 10.1158/0008-5472.CAN-12-0549. Epub 2012 Nov 9. Cancer Res. 2012. PMID: 23144293 Review.
IDO Targeting in Sarcoma: Biological and Clinical Implications.
Nafia I, Toulmonde M, Bortolotto D, Chaibi A, Bodet D, Rey C, Velasco V, Larmonier CB, Cerf L, Adam J, Le Loarer F, Savina A, Bessede A, Italiano A. Nafia I, et al. Among authors: bessede a. Front Immunol. 2020 Mar 5;11:274. doi: 10.3389/fimmu.2020.00274. eCollection 2020. Front Immunol. 2020. PMID: 32194552 Free PMC article.
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease.
Lim CK, Fernández-Gomez FJ, Braidy N, Estrada C, Costa C, Costa S, Bessede A, Fernandez-Villalba E, Zinger A, Herrero MT, Guillemin GJ. Lim CK, et al. Among authors: bessede a. Prog Neurobiol. 2017 Aug;155:76-95. doi: 10.1016/j.pneurobio.2015.12.009. Epub 2016 Apr 9. Prog Neurobiol. 2017. PMID: 27072742 Review.
40 results